The UK isn't popular in some international circles, but it is leading the help for poorer countries to end COVID-19
The United Nations (UN) has welcomed a series of recent pledges made by governments and other donors to help the wider international fight to bolster access to lifesaving tests, treatments and vaccines to end COVID-19.
Leading the way with the recent pledges to the Access to COVID-19 Tools (ACT) Accelerator¬ has been the UK, with its £571 million (US$ 732 million) gift for the COVAX pillar, of which up to £500 million (US$ 641 million) is to support low- and middle-income countries. This includes a commitment to match £1 for every $4 committed by others, up to £250 million.
The gift is perhaps welcome for the UK's international standing, given the rocky path of its exit from the European Union.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze